Segall Bryant & Hamill LLC Takes $43.63 Million Position in AbbVie Inc. $ABBV

Posted by Stanley Muller on Aug 1st, 2026

Segall Bryant & Hamill LLC purchased a new stake in AbbVie Inc. (NYSE:ABBV – Free Report) in the 1st quarter, HoldingsChannel.com reports. The fund purchased 191,648 shares of the company’s stock, valued at approximately $43,634,000.

A number of other institutional investors have also recently added to or reduced their stakes in ABBV. Vanguard Group Inc. grew its holdings in AbbVie by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 180,779,699 shares of the company’s stock valued at $41,306,353,000 after buying an additional 3,032,438 shares in the last quarter. State Street Corp increased its position in AbbVie by 1.4% during the fourth quarter. State Street Corp now owns 80,940,931 shares of the company’s stock worth $18,494,193,000 after purchasing an additional 1,119,274 shares during the last quarter. Geode Capital Management LLC raised its stake in AbbVie by 10.4% during the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock worth $10,179,099,000 after purchasing an additional 4,190,487 shares during the period. Bank of America Corp DE boosted its holdings in AbbVie by 1.4% in the 4th quarter. Bank of America Corp DE now owns 25,824,399 shares of the company’s stock valued at $5,900,617,000 after purchasing an additional 356,394 shares during the last quarter. Finally, Norges Bank acquired a new position in AbbVie in the 4th quarter valued at about $5,865,055,000. Hedge funds and other institutional investors own 70.23% of the company’s stock.

More AbbVie News

Here are the key news stories impacting AbbVie this week:

Positive Sentiment: Solid second-quarter results: AbbVie reported adjusted EPS of $3.65, above the $3.60 consensus estimate, while revenue rose 10.2% year over year to $16.99 billion. Reuters article
Positive Sentiment: Immunology and neuroscience remained growth drivers: Skyrizi revenue reached $5.505 billion and Rinvoq generated $2.525 billion, while neuroscience revenue increased 20.3% to $3.228 billion. Botox also showed signs of stabilization, supporting the company’s diversified growth profile. AbbVie earnings release
Positive Sentiment: Pipeline and portfolio expansion: AbbVie is advancing a global Phase 2/3 combination study in acute myeloid leukemia and recently received European approval for Rinvoq in severe alopecia areata, adding potential long-term growth opportunities. AML trial article
Neutral Sentiment: Near-term guidance was broadly in line: Third-quarter adjusted EPS guidance of $3.84–$3.88 brackets the $3.85 consensus estimate, but revenue guidance of approximately $17.2 billion is slightly below the $17.3 billion analyst forecast.
Negative Sentiment: Full-year EPS outlook was reduced: AbbVie lowered 2026 adjusted EPS guidance to $13.87–$14.07 from $13.91–$14.11. The revised range includes an estimated $0.14-per-share dilution from the planned $10.9 billion acquisition of Apogee Therapeutics, pushing the midpoint below Wall Street expectations. Zacks guidance article
Negative Sentiment: Acquisition and execution concerns weigh on sentiment: Investors are balancing Apogee’s potential to strengthen AbbVie’s immunology pipeline against its immediate earnings dilution, while oncology revenue fell 1.5% and aesthetics revenue was essentially flat during the quarter.

Analyst Ratings Changes

A number of analysts have recently issued reports on ABBV shares. Canaccord Genuity Group raised their price target on shares of AbbVie from $273.00 to $282.00 and gave the stock a “buy” rating in a report on Wednesday, July 22nd. Wells Fargo & Company upped their price objective on AbbVie from $260.00 to $295.00 and gave the company an “overweight” rating in a report on Friday, July 10th. Barclays increased their price objective on AbbVie from $275.00 to $300.00 and gave the stock an “overweight” rating in a research report on Wednesday. Guggenheim raised their target price on AbbVie from $249.00 to $261.00 and gave the stock a “buy” rating in a research note on Thursday, July 9th. Finally, Weiss Ratings restated a “hold (c)” rating on shares of AbbVie in a research report on Monday, June 8th. Two research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have given a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $269.29.

View Our Latest Stock Report on ABBV

AbbVie Price Performance

Shares of ABBV opened at $251.33 on Friday. AbbVie Inc. has a 1-year low of $187.62 and a 1-year high of $267.47. The stock has a market cap of $444.05 billion, a PE ratio of 123.81, a P/E/G ratio of 0.85 and a beta of 0.30. The firm has a 50-day simple moving average of $239.10 and a two-hundred day simple moving average of $224.05.

AbbVie (NYSE:ABBV – Get Free Report) last released its quarterly earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $3.61 by $0.04. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The business had revenue of $16.99 billion for the quarter, compared to the consensus estimate of $16.78 billion. During the same period in the previous year, the firm earned $2.97 EPS. The business’s revenue was up 10.2% on a year-over-year basis. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. As a group, sell-side analysts expect that AbbVie Inc. will post 14.14 earnings per share for the current fiscal year.

AbbVie Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Shareholders of record on Wednesday, July 15th will be given a $1.73 dividend. The ex-dividend date of this dividend is Wednesday, July 15th. This represents a $6.92 dividend on an annualized basis and a yield of 2.8%. AbbVie’s payout ratio is presently 340.89%.

About AbbVie

(Free Report)

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.